No-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutations

治疗具有 ASXL1 无义突变的骨髓恶性肿瘤的严肃方法

• 批准号: 8830950
• 负责人: Mingjiang Xu
• 金额: $ 20.03万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-03 至 2016-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8830950
• 关键词: Acute Myelocytic Leukemia; Alleles; Amino Acids; Aminoglycosides; Animal Model; Attenuated; C-terminal; Cell physiology; Cells; Cessation of life; Chromosomes; Clinical Trials; Comb animal structure; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Data; Development; Disease; Dysmyelopoietic Syndromes; Dystrophin; Frequencies; Generations; Genes; Gentamicins; Goals; Health; Hematologic Neoplasms; Hematopoietic; Histone H3; Human; In Vitro; Intellectual functioning disability; Length; Location; Maps; Mediating; Methylation; Monitor; Mus; Muscular Dystrophies; Mutate; Mutation; Myelofibrosis; Myelogenous; Myeloproliferative disease; N-terminal; Nonsense Codon; Nonsense Mutation; Opitz syndrome; Pathogenesis; Patients; Peptides; Phenotype; Placebos; Plants; Population; Protein Truncation; Proteins; Reading; Role; Sampling; Specimen; Stem cells; Terminator Codon; Testing; Therapeutic; Translations; base; homeodomain; in vivo; innovation; leukemia; loss of function; malformation; mouse model; novel; outcome forecast; overexpression; premature; prevent; protein purification; reading ability; sex; stem; success; transgene expression; treatment strategy

DESCRIPTION (provided by applicant): Read-through compounds (RTCs) are capable of promoting ribosomal read-through of premature termination codons (PTCs), resulting in substitution of the PTC with an amino acid and generation of full-length protein product. The RTCs include aminoglycosides (such as gentamicin) and non-aminoglycoside (such as ataluren and RTC13) compounds, which are specific for PTCs and do not interfere with normal stop codons. These RTCs have been shown to have read-through activity on nonsense mutations in the CFTR and the dystrophin genes in both cultures and animal models. Intriguingly, clinical trials in patients with nonsense mutation muscular dystrophy and cystic fibrosis showed that RTCs induced some expression of functional, previously missing, proteins in both diseases and had some therapeutic benefits. Additional sex comb-like 1 (ASXL1) is mutated at high frequencies in multiple forms of myeloid malignancies, including MDS, MPN, CMML, and AML. De novo ASXL1 mutations cause Bohring-Opitz syndrome. Mutations in ASXL1 are nonsense/frameshift, leading to loss-of-function by truncating the critical PHD domain. Mutations in ASXL1 are associated with poor prognosis. Approximately 1/3 of the myeloid malignancy cases with ASXL1 mutations are nonsense, which are appealing targets for PTC-based read- through. In this application, we will explore the hypothesis that RTCs are capable of reversing ASXL1-PTCs and induce adequate amount of full-length, functional ASXL1 expression in hematopoietic stem/progenitor cells (HSCs/HSPCs), therefore attenuating the ASXL1-deficiency/haploinsufficiency mediated abnormal HSC/HPC function and hematological phenotype. Three specific aims are proposed to test this hypothesis. Aim 1: To determine the ability of RTCs (gentamicin, ataluren and RTC13) to reverse Asxl1-PTCs and yield adequate amount of full-length, functional Asxl1 expression in various hematopoietic cell populations from Asxl1-PTCTg;MxCre mice. Aim 2: To assess the therapeutic potential of RTCs by examining if RTC treatment is capable of preventing or curing the Asxl1-deficiency mediated pathogenesis of myeloid malignancies in Asxl1f/f;MxCre;Asxl1-PTCTg mice (inducible Asxl1-inactivation with simultaneous Asxl1-PTC transgene expression). Aim 3: To validate the therapeutic potential of RTCs using primary cells from myeloid malignancy patients with ASXL1 nonsense mutations. We will determine the ability of RTCs in promoting ribosomal read- through of different ASXL1-PTCs (TGA, TAA, TAG) in various hematopoietic cell populations from myeloid malignancy patients with ASXL1 nonsense mutations. We will examine if RTC treatment is capable of correcting/attenuating the abnormal cellular function of myeloid malignancy HSC/HPCs with ASXL1 nonsense mutations in NSG mice. Success of these studies will advance this novel treatment strategy into not only ASXL1-PTC diseases, but also many hematological malignancies due to nonsense mutation-mediated early termination of translation.

说明书(申请人提供)：通读化合物(RTCs)能够促进过早终止密码子(PTCs)的核糖体通读，导致PTC被氨基酸取代并产生全长蛋白质产品。Rtcs包括氨基糖苷类(如庆大霉素)和非氨基糖苷类化合物(如ataluren和rtc13)，它们是ptcs特异的，不干扰正常的终止密码子。在培养和动物模型中，这些RTCs已经被证明对CFTR和dystrophin基因的无义突变具有通读活性。有趣的是，对无义突变型肌营养不良和囊性纤维化患者的临床试验表明，RTCs在这两种疾病中都诱导了一些以前缺失的功能性蛋白质的表达，并具有一些治疗益处。在多种类型的髓系恶性肿瘤中，包括MDS、MPN、CMML和AML，附加性梳状突变型1(ASXL1)的突变频率很高。新的ASXL1突变导致Bohring-Opitz综合征。ASXL1中的突变是无意义的/移码，通过截断关键的PHD结构域而导致功能丧失。ASXL1基因突变与预后不良有关。大约三分之一的带有ASXL1突变的髓系恶性肿瘤病例都是无稽之谈，这是基于PTC的通读的吸引人的靶点。在这一应用中，我们将探索RTCs能够逆转ASXL1-PTCs的假设，并在造血干/祖细胞(HSCs/HSPC)中诱导足够数量的全长、功能性ASXL1表达，从而减轻ASXL1缺陷/单倍体不足介导的异常HSC/HPC功能和血液学表型。为了检验这一假说，本文提出了三个具体目标。目的：检测RTCs(庆大霉素、阿托林和RTC13)逆转ASXL1-PTCs的能力，并在ASXL1-PTCTg；MxCre小鼠的不同造血细胞群中产生足够量的全长、功能性ASXL1表达。目的：在Asxl1f/f、MxCre、ASXL1-PTCTg小鼠(可诱导ASXL1失活的同时ASXL1-PTC转基因表达)小鼠中，检测RTC治疗是否能够预防或治愈ASXL1缺陷介导的髓系恶性肿瘤的发病机制，以评价RTCs的治疗潜力。目的：利用携带ASXL1无义突变的髓系恶性肿瘤患者的原代细胞，验证RTCs的治疗潜力。我们将确定RTCs促进不同ASXL1-PTCs(TGA、TAA、TAG)在具有ASXL1无义突变的髓系恶性肿瘤患者的不同造血细胞群中的能力。我们将检验RTC治疗是否能够纠正/减弱带有ASXL1无义突变的髓系恶性肿瘤HSC/HPC在NSG小鼠中的异常细胞功能。这些研究的成功将使这一新的治疗策略不仅适用于ASXL1-PTC疾病，还将应用于由于无义突变介导的提前终止翻译而导致的许多血液系统恶性肿瘤。